Centre of Evidence of Dermatology Best practice guidelines

Guidelines hidradenitis suppurativa Updated on august 2019


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

Comorbidities and associated disease

Back to decision-making tree Print last updated on 01/04/2020

Follicular diseases

Follicular diseases can precede the first symptoms of HS by several years:

Inflammatory diseases

Digestive tract or rheumatism inflammatory diseases can be associated, justifying systematic investigation of symptoms associated with the following pathologies during patient interviews:

Skin cancers

A few observational studies have highlighted a higher prevalence of epidermoid skin cancer in patients with HS (approximately 4 times greater risk of developing an epidermoid carcinoma, regardless of anatomical location).

Cardiovascular diseases

Different epidemiological studies suggest that there is an elevated risk of cardiovascular disease in patients with HS (especially in severe cases) and of an associated metabolic syndrome (including obesity, dyslipidemia, diabetes or high blood pressure).

Metabolic syndrome

Metabolic syndrome is defined as the presence of at least 3 of the following criteria:
Waist > 102 cm, men
> 88 cm, women
Triglycerides > 1,50 g/L
HDL cholesterol < 0,40 g/L men
< 0,50 g/Lwomen
Blood pressure ≥ 130/85 mmHg
Fasting blood sugar level > 1,10 g/L

The patient should be referred to a specialist in case of doubt.

  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.

read associated measures / comorbidities

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
10 cité Malesherbes
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86